Stage (next event)
Phase 3 Topline Data
Catalyst Info & Data Links
TITLE: Rezafungin for Treatment of Fungal Infections - Phase 3
ClinicalTrial.gov (NCT03667690): Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
End of 2021
11-05-2020 2020 Third Quarter Financial Results
Mechanism of Action
MECHANISM OF ACTION
Rezafungin is a novel echinocandin antifungal and the only once-weekly drug candidate being developed for the first-line treatment and prevention of serious invasive fungal infections. Rezafungin has a unique pharmacokinetic profile with a prolonged half-life and front-loaded plasma exposure which, in contrast to all other echinocandins, allows for once-weekly IV therapy for inpatient and outpatient use.
Updated by JM
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post